Can a blinded crossover trial help people who stopped statins due to side effects restart them successfully?
What the Evidence Shows
What we've found so far suggests that a blinded crossover trial may help some people who stopped statins due to side effects successfully restart them. The evidence we've reviewed leans toward this approach being useful for a meaningful number of individuals.
Our analysis of the available research shows that when people who discontinued statins because of side effects take part in a blinded crossover trial—where they receive the actual statin, a placebo, and no pill, without knowing which is which—about half are able to restart the statin and continue taking it within six months . This finding comes from one assertion supported by 82.0 studies, with no studies refuting it. While we can’t say why this happens, the pattern suggests that for some, the symptoms they experienced may not have been directly caused by the statin itself—or that the uncertainty of knowing whether they were taking the drug played a role in symptom perception.
We don’t yet know which factors predict who will successfully restart, nor do we fully understand the role of expectation or awareness in symptom reporting. But what we can say is that this method appears to help reestablish tolerance in a significant portion of those who previously couldn’t take statins.
It’s important to note that our current analysis is based on limited types of evidence—specifically one broad assertion with indirect support. We’re not claiming this works for everyone, nor are we saying the side effects people felt weren’t real. We’re simply reporting that the evidence we’ve reviewed shows a trend: blinding and retesting seem to change outcomes for many.
Practical takeaway: If you stopped statins due to side effects, a structured trial where you—and your doctor—don’t know if you’re taking the drug might help determine if you can tolerate it after all.